Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of a set of genes associated with response to interleukin-2 and interferon-α combination therapy for renal cell carcinoma through genome-wide gene expression profiling.
Mizumori O, Zembutsu H, Kato Y, Tsunoda T, Miya F, Morizono T, Tsukamoto T, Fujioka T, Tomita Y, Kitamura T, Ozono S, Miki T, Naito S, Akaza H, Nakamura Y. Mizumori O, et al. Among authors: fujioka t. Exp Ther Med. 2010 Nov;1(6):955-961. doi: 10.3892/etm.2010.148. Epub 2010 Sep 10. Exp Ther Med. 2010. PMID: 22993625 Free PMC article.
Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling.
Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, Namiki M, Kohri K, Matsushita Y, Fujioka T, Nakamura Y. Takata R, et al. Among authors: fujioka t. Clin Cancer Res. 2005 Apr 1;11(7):2625-36. doi: 10.1158/1078-0432.CCR-04-1988. Clin Cancer Res. 2005. PMID: 15814643 Clinical Trial.
Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W, Yoshioka H, Daigo Y, Nasu Y, Kumon H, Konaka H, Namiki M, Tozawa K, Kohri K, Tanji N, Yokoyama M, Shimazui T, Akaza H, Mizutani Y, Miki T, Fujioka T, Shuin T, Nakamura Y, Nakagawa H. Tamura K, et al. Among authors: fujioka t. Cancer Res. 2007 Jun 1;67(11):5117-25. doi: 10.1158/0008-5472.CAN-06-4040. Cancer Res. 2007. PMID: 17545589
Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level.
Akaza H, Tsukamoto T, Fujioka T, Tomita Y, Kitamura T, Ozono S, Miki T, Naito S, Zembutsu H, Nakamura Y. Akaza H, et al. Among authors: fujioka t. Jpn J Clin Oncol. 2011 Aug;41(8):1023-30. doi: 10.1093/jjco/hyr067. Epub 2011 Jun 4. Jpn J Clin Oncol. 2011. PMID: 21642665 Clinical Trial.
Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs.
Ashida S, Nakagawa H, Katagiri T, Furihata M, Iiizumi M, Anazawa Y, Tsunoda T, Takata R, Kasahara K, Miki T, Fujioka T, Shuin T, Nakamura Y. Ashida S, et al. Among authors: fujioka t. Cancer Res. 2004 Sep 1;64(17):5963-72. doi: 10.1158/0008-5472.CAN-04-0020. Cancer Res. 2004. PMID: 15342375
1,259 results